ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $643,525 | -94.6% | 32,080 | -92.3% | 0.00% | -100.0% |
| Q2 2023 | $11,826,366 | +1434.0% | 419,226 | +835.3% | 0.01% | – |
| Q1 2023 | $770,973 | +2.4% | 44,824 | +19.9% | 0.00% | – |
| Q4 2022 | $753,155 | -49.4% | 37,396 | -45.5% | 0.00% | -100.0% |
| Q3 2022 | $1,487,000 | +134.9% | 68,654 | +204.7% | 0.00% | – |
| Q2 2022 | $633,000 | -58.6% | 22,528 | -32.0% | 0.00% | -100.0% |
| Q1 2022 | $1,530,000 | -48.0% | 33,152 | -5.2% | 0.00% | 0.0% |
| Q4 2021 | $2,942,000 | +30.6% | 34,986 | +3.5% | 0.00% | 0.0% |
| Q3 2021 | $2,253,000 | +89.3% | 33,803 | +51.1% | 0.00% | 0.0% |
| Q2 2021 | $1,190,000 | +27.4% | 22,365 | +3.9% | 0.00% | 0.0% |
| Q1 2021 | $934,000 | -23.1% | 21,534 | -7.9% | 0.00% | 0.0% |
| Q4 2020 | $1,214,000 | +492.2% | 23,377 | +273.7% | 0.00% | – |
| Q3 2020 | $205,000 | -18.7% | 6,255 | +19.5% | 0.00% | – |
| Q2 2020 | $252,000 | – | 5,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
| Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
| Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
| 5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
| Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
| Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
| First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
| Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |